Hims & Hers stock tumbles as Novo Nordisk terminates Wegovy deal. BofA warns of significant further downside in the HIMS ...

Hims & Hers (HIMS) stock plummeted nearly 35% Monday after Novo Nordisk (NVO) announced it was ending a collaboration to make its blockbuster weight-loss drug, Wegovy, available on Hims' telehealth ...

CHICAGO -- Semaglutide (Ozempic) reduced glucose levels and weight among patients with type 1 diabetes and obesity, a ...

First, the stock has sliced through two support levels. Shares broke through their 50-day moving average on Monday for the ...

Amgen (NASDAQ:AMGN) announced on Monday that its new weight loss treatment, MariTide, resulted in an average weight loss of ...